THERAPY DOSSIER · th-7010502a9cb9

Recombinant human IL-37, full-length and processed forms

Biologic

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Spinal cord injury
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 6

1 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

NCT03297827 ↗Injury indicationPhase not recordedcompleted

BIOMARKER-LEVEL SURROGATE: Prospective Cytokine Registry Database of Ischemic and Hemorrhagic Stroke Patients

Acute Stroke · Ischemic Stroke · Hemorrhagic Stroke

Enrolment: 12 · Results not recorded

NCT05640037 ↗Phase not recordedcompleted

BIOMARKER-LEVEL SURROGATE (observational, endogenous IL-37): Urine Interleukin-37 as a Biomarker of Mortality Risk in Sepsis

Sepsis

Enrolment: 99 · Results not recorded

NCT03161301 ↗Phase not recordedcompleted

BIOMARKER-LEVEL SURROGATE: Role of IL-37 Genetic Variants in Modulating Innate Immune Response to Periodontal Pathogens

Periodontal Diseases

Enrolment: 86 · Results not recorded

NCT03088228 ↗Phase not recordedcompleted

BIOMARKER-LEVEL SURROGATE: Maternal Periodontal Status and GCF Levels of IL-6, IL-35 and IL-37 in Preeclampsia

Preeclampsia · Periodontal Diseases

Enrolment: 80 · Results not recorded

NCT04482777 ↗Phase not recordedunknown

BIOMARKER-LEVEL SURROGATE: IL-37, T Lymphocytes and NK Cells in Pathogenesis of Immune Thrombocytopenia

ITP

Enrolment: 90 · Results not recorded

NCT05301153 ↗Phase not recordedunknown

BIOMARKER-LEVEL SURROGATE: Expression Levels of IL-37 and Correlation With Autoantibodies in Myasthenia Gravis

Myasthenia Gravis

Enrolment: 82 · Results not recorded

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 26787859 ↗2016Reported benefit

Beneficial effects of IL-37 after spinal cord injury in mice.

MouseSpinal cord injuryContusionhuman IL-37 transgenic (hIL-37tg) and wild-type micesingle intraspinal injectionafter the injury

Model: Spinal cord contusion injury

Transgenic hIL-37tg mice showed increased myelin and neuronal sparing, 2.5-fold greater forced treadmill speed and roughly 80 per cent lower IL-6 in the injured cord. A single intraspinal injection of either form of recombinant IL-37 into wild-type mice improved open field and treadmill locomotor p…

Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.7. Machine-extracted fields require source verification.

Loading the evidence…